A 67-year-old woman with tertiary hyperparathyroidism and end-stage renal disease on hemodialysis has persistent hypercalcemia (calcium 12.8 mg/dL) despite maximal medical management with cinacalcet and vitamin D restriction. She has severe pruritus, calciphylaxis, and vascular calcifications. All four parathyroid glands are enlarged on imaging. Evaluate the optimal surgical strategy considering her complex medical status and need for ongoing dialysis access.
A 30-year-old man presents with a 6 cm adrenal mass discovered incidentally. Biochemical workup shows elevated 24-hour urine metanephrines and plasma free metanephrines. He also has elevated serum calcium, PTH, and a pancreatic head mass on CT. Genetic testing confirms MEN 2B syndrome. Evaluate the management priorities and sequencing of interventions.
A 38-year-old woman with primary hyperparathyroidism (calcium 11.8 mg/dL, PTH 185 pg/mL) has negative sestamibi scan and ultrasound. She desires surgical cure and has no medical contraindications. She has a Z-score of -2.8 on DEXA scan and a history of recurrent kidney stones. Evaluate the surgical approach and expected outcomes.
A 55-year-old woman presents with a 4 cm thyroid nodule. FNA shows Hurthle cell neoplasm (follicular variant). Preoperative ultrasound shows no lymphadenopathy. She undergoes thyroid lobectomy, and final pathology reveals a 3.8 cm Hurthle cell carcinoma with capsular invasion but no vascular invasion. Analyze the pathology findings and determine the next step in management.
A 42-year-old woman with a family history of pheochromocytoma undergoes resection of a 5 cm right adrenal mass. Preoperatively, she was adequately alpha-blocked with phenoxybenzamine. During tumor manipulation, her blood pressure rises to 220/130 mmHg despite anesthesia deepening. Immediately after tumor removal, her blood pressure drops to 70/40 mmHg. Analyze the hemodynamic changes and determine management priorities.
A 48-year-old man presents with hypertension, hypokalemia (K+ 2.8 mEq/L), and metabolic alkalosis. Plasma aldosterone is elevated and plasma renin is suppressed. CT shows a 2.5 cm left adrenal mass with 15 Hounsfield units. Adrenal vein sampling shows lateralization to the left adrenal gland. Analyze the pathophysiology and determine the best treatment.
A 62-year-old woman undergoes total thyroidectomy for Graves' disease. On postoperative day 1, she develops perioral numbness, tingling in her fingertips, and carpopedal spasm. Serum calcium is 7.2 mg/dL. What is the most appropriate immediate management?
A 35-year-old woman with MEN 2A syndrome (RET proto-oncogene mutation) presents for screening. She has no thyroid nodules on ultrasound and normal calcitonin levels. Her 8-year-old daughter tested positive for the same RET mutation. What is the most appropriate management for the daughter?
A 58-year-old man with persistent hypercalcemia (calcium 12.5 mg/dL) and elevated PTH (150 pg/mL) undergoes parathyroidectomy. Intraoperative PTH level drops from 145 pg/mL at baseline to 95 pg/mL at 10 minutes post-excision of a suspected adenoma. What is the next best step?
A 45-year-old woman presents with a 2 cm thyroid nodule. Fine-needle aspiration shows papillary thyroid carcinoma. Ultrasound shows no lymphadenopathy. She has no family history of thyroid cancer and no history of radiation exposure. What is the most appropriate surgical management?
Explanation: ***Total parathyroidectomy with forearm autotransplantation*** - In **tertiary hyperparathyroidism** with four-gland enlargement, this procedure provides definitive treatment while allowing for easier access if **recurrent hyperplasia** occurs. - Placing the tissue in the **forearm** avoids risky neck re-explorations in the future and is the standard for patients who may remain on long-term dialysis. *Single adenoma resection guided by sestamibi* - This approach is inappropriate because **tertiary hyperparathyroidism** involves **multiglandular hyperplasia**, not a single solitary adenoma. - Imaging with **sestamibi** is less reliable in renal patients, and leaving three hyperplastic glands would lead to surgical failure. *Subtotal parathyroidectomy (3.5 gland resection)* - While a valid option for some, it carries a higher risk of **persistent hypercalcemia** or recurrence within the neck remnant compared to total resection. - In patients with **calciphylaxis** and severe symptoms, many surgeons prefer total resection to ensure immediate clearance of excess **parathyroid hormone**. *Total parathyroidectomy without autotransplantation* - This technique leads to permanent **hypoparathyroidism**, which is difficult to manage and can result in **adynamic bone disease**. - It is generally reserved for patients who are not candidates for future transplantation and have severe, life-threatening **hypercalcemia** where no hormonal replacement is desired. *Medical management escalation with denosumab* - The patient has already failed **maximal medical management** including **cinacalcet**, and her severe **calciphylaxis** is a surgical emergency. - **Denosumab** does not address the underlying autonomous parathyroid hyperplasia and is not a definitive treatment for **tertiary hyperparathyroidism**.
Explanation: ***Adrenalectomy first, then thyroidectomy, then other tumors*** - Prioritizing **pheochromocytoma** resection is critical to avoid a life-threatening **hypertensive crisis** during subsequent surgeries. - Adequate medical preparation with **alpha-blockade** followed by beta-blockade is mandatory before any surgical intervention in these patients. *Simultaneous thyroidectomy and bilateral adrenalectomy* - Simultaneous procedures significantly increase **perioperative risk** and operative time without ensuring hemodynamic stability during the thyroid portion. - Managing the **catecholamine surge** from a pheochromocytoma is safer when performed as a separate, initial stage. *Medical management of pheochromocytoma then parathyroidectomy* - While **alpha-blockade** is necessary, the question asks for the sequence of surgical interventions, where adrenalectomy must precede other operations. - This patient presents with features suggestive of **MEN 2B**, which classically does not include hyperparathyroidism, unlike **MEN 1** or **MEN 2A**. *Immediate thyroidectomy followed by staged procedures* - Performing a **thyroidectomy** first is contraindicated because the stress of surgery and anesthesia can trigger a **pheochromocytoma crisis**. - Even if medullary thyroid carcinoma is aggressive, the risk of immediate **intraoperative death** from pheochromocytoma takes precedence. *Pancreatic surgery first due to mass effect* - Although a **pancreatic head mass** is present (suggestive of MEN 1 overlap or separate pathology), it is not the immediate life-threatening priority. - Operating on the pancreas before controlling and removing the **pheochromocytoma** exposes the patient to severe hemodynamic instability.
Explanation: ***Bilateral neck exploration with identification of all four glands*** - When **preoperative localization** studies (Sestamibi and Ultrasound) are negative, a **bilateral neck exploration** is the gold standard to identify the source of primary hyperparathyroidism. - This patient has clear indications for surgery including **nephrolithiasis**, a **Z-score of -2.8** (osteoporosis), and symptomatic hypercalcemia, making surgical intervention necessary despite negative imaging. *Defer surgery until localization studies are positive* - **Negative imaging** does not rule out primary hyperparathyroidism or contraindicate surgery when biochemical evidence is clear. - Deferring treatment would risk further **bone loss** and recurrent **kidney stones** in a patient who already meets surgical criteria. *Minimally invasive parathyroidectomy of the largest gland* - **Minimally invasive parathyroidectomy (MIP)** requires precise preoperative localization to guide the surgeon to a specific quadrant. - Attempting MIP without localization increases the risk of **surgical failure** and missing ectopic or multiglandular disease. *Medical management with cinacalcet and bisphosphonates* - **Medical management** is generally reserved for patients who are not surgical candidates or those who refuse surgery. - While cinacalcet lowers **PTH** and calcium, it does not provide a **permanent cure** for the underlying adenoma or hyperplasia and is not the first-line choice for a young, fit patient. *Intraoperative PTH-guided focused exploration* - **Focused exploration** relies on knowing which side to explore first; without imaging, there is no target for a "focused" approach. - While **intraoperative PTH** (ioPTH) monitoring is a useful adjunct to confirm cure, it does not replace the need for a comprehensive **bilateral search** when imaging is nonlocalizing.
Explanation: ***Completion thyroidectomy within 2 weeks*** - For **Hurthle cell carcinoma** (HCC), a completion thyroidectomy is indicated when a malignancy is confirmed post-lobectomy, especially given HCC's aggressive nature and size approaching **4 cm**. - Total thyroidectomy is necessary to facilitate future surveillance using **serum thyroglobulin** levels and to prepare for potential **radioactive iodine (RAI)** therapy if needed. *Radioactive iodine ablation without further surgery* - **Radioactive iodine (RAI)** therapy cannot be effectively performed if a remnant thyroid lobe is still present, as the normal tissue will sequester the iodine. - **Hurthle cells** are historically less iodine-avid than other follicular cells, making surgical clearance of all thyroid tissue even more critical before considering RAI. *Observation with ultrasound surveillance every 6 months* - **Observation** is generally reserved for low-risk papillary microcarcinomas or minimally invasive follicular carcinomas <1-2 cm without high-risk features. - The presence of **capsular invasion** and the histological subtype of **Hurthle cell carcinoma** in a 3.8 cm lesion represent a higher risk that mandates definitive surgical management. *External beam radiation therapy* - **External beam radiation** is not a primary treatment for localized Hurthle cell carcinoma and is typically reserved for **palliative care** or unresectable local recurrence. - It does not replace the standard of care for surgical management of a resectable **thyroid malignancy**. *Prophylactic modified radical neck dissection* - **Prophylactic neck dissection** is not recommended for Hurthle cell carcinoma because it primarily spreads **hematogenously** rather than through lymphatic channels. - Surgical management of the neck is only indicated if there is clinical or radiological evidence of **cervical lymphadenopathy**, which was absent in this patient.
Explanation: ***Immediate aggressive fluid resuscitation and vasopressors*** - Sudden **hypotension** after tumor removal occurs because the body is no longer receiving the massive surge of **catecholamines** while existing **alpha-blockade** (phenoxybenzamine) persists. - Management requires **large-volume intravenous fluids** to address pre-existing **volume depletion** and vasopressors to maintain mean arterial pressure until the vascular tone is restored. *Continue phenoxybenzamine and observe* - Phenoxybenzamine is a **non-competitive alpha-antagonist** used preoperatively to control hypertension; it has a long half-life and cannot be reversed quickly. - Continuing observation without intervention in a patient with a blood pressure of **70/40 mmHg** would lead to organ malperfusion and **cardiovascular collapse**. *Administer phentolamine for hypertensive crisis* - Phentolamine is appropriate for managing the **intraoperative hypertensive surge** caused by tumor manipulation, but it is contraindicated once the patient is hypotensive. - Giving a vasodilator during the post-resection **hypotensive phase** would exacerbate the low blood pressure and worsen the clinical state. *Emergency re-exploration for bleeding* - Although postoperative hemorrhage is a concern, the timing of this collapse matches the **physiologic withdrawal** of catecholamines precisely upon ligation of the adrenal vein. - Hemodynamic instability should first be treated with **fluid boluses** and pressors; surgical re-exploration is reserved for confirmed cases of **hemoperitoneum**. *Decrease anesthesia depth and give beta-blockers* - Decreasing anesthesia depth may help slightly with blood pressure but is insufficient to counteract the loss of **endogenous vasopressors**. - Giving **beta-blockers** in the setting of hypotension is dangerous as it reduces **cardiac output** and compensatory tachycardia, further decreasing blood pressure.
Explanation: ***Left laparoscopic adrenalectomy*** - The patient presents with **Conn syndrome** (primary hyperaldosteronism), confirmed by **elevated aldosterone**, **suppressed renin**, and lateralization on **adrenal vein sampling (AVS)**. - **Unilateral laparoscopic adrenalectomy** is the gold-standard curative treatment for an **aldosterone-producing adenoma (APA)** lateralized to one side. *Bilateral adrenalectomy* - This procedure results in **permanent adrenal insufficiency** (Addisonian state), requiring lifelong glucocorticoid and mineralocorticoid replacement. - It is not indicated for **unilateral disease** and is rarely used even for bilateral hyperplasia due to high morbidity. *Right laparoscopic adrenalectomy* - CT and **adrenal vein sampling (AVS)** clearly indicate the pathology and lateralization are on the **left side**. - Removing the healthy right gland would not resolve the **hyperaldosteronism** and would leave the diseased left gland intact. *Medical management followed by repeat imaging in 6 months* - Delayed treatment exposes the patient to the chronic cardiovascular and renal risks associated with **uncontrolled hypertension** and **hypokalemia**. - Since the lesion is biochemically active and **lateralized**, surgical intervention is indicated immediately rather than observation. *Medical management with spironolactone indefinitely* - This is the treatment of choice for **bilateral adrenal hyperplasia (BAH)** or patients who are unfit for surgery. - For a surgical candidate with **unilateral disease**, surgery is preferred as it offers a potential **complete cure** and avoids the side effects of long-term mineralocorticoid receptor antagonists.
Explanation: ***Intravenous calcium gluconate 1-2 ampules over 10 minutes*** - The patient is presenting with **symptomatic hypocalcemia** (perioral numbness, carpopedal spasm) which is a medical emergency requiring rapid correction. - **Calcium gluconate** is preferred over calcium chloride for peripheral administration because it is less likely to cause **tissue necrosis** if extravasation occurs. *Oral calcium carbonate 1000 mg three times daily* - **Oral supplementation** is insufficient for patients presenting with acute, severe symptoms of tetany as it lacks the rapid absorption needed to prevent complications. - This route is typically reserved for **asymptomatic** patients or as long-term maintenance therapy once the acute phase is controlled. *Calcitriol 0.25 mcg twice daily* - This is an active form of **Vitamin D** used to enhance intestinal calcium absorption, which takes several hours to days to become effective. - It is used for the management of **chronic hypoparathyroidism** but is not an appropriate standalone treatment for immediate acute management of tetany. *Observation with repeat calcium in 4 hours* - Delaying treatment in a patient with **carpopedal spasms** and serum calcium below 7.5 mg/dL risks progression to **seizures** or life-threatening **arrhythmias**. - Observation is only appropriate for mild, asymptomatic postoperative hypocalcemia where calcium levels are stable and monitored. *Oral calcium with vitamin D supplementation* - While this combination is standard for **postoperative maintenance**, it does not provide the immediate rise in ionized calcium required to halt **neuromuscular irritability**. - The onset of action for this regimen is too slow to treat the clinical signs of **hypocalcemic tetany**.
Explanation: ***Prophylactic total thyroidectomy now*** - In patients with **MEN 2A** and a confirmed **RET proto-oncogene mutation**, the risk of developing **medullary thyroid carcinoma (MTC)** is nearly 100%. - Current guidelines recommend prophylactic surgery for the **intermediate-risk** mutations (typical of MEN 2A) by age **5 to 10 years**; since the daughter is 8, surgery is indicated now to prevent malignancy. *Observation until calcitonin becomes elevated* - Waiting for **elevated calcitonin** levels means that **C-cell hyperplasia** or overt MTC may already be present, defeating the purpose of prophylaxis. - Prophylactic management aims to intervene before biochemical or clinical evidence of disease appears to maximize survival. *Annual calcitonin screening until age 18* - Annual screening is insufficient because MTC in MEN 2A is highly aggressive and often develops in **early childhood**. - Delaying definitive treatment until age 18 poses an unacceptably high risk of **metastatic disease** at the time of diagnosis. *Thyroid ultrasound every 6 months* - **Ultrasound** is not sensitive enough to detect the early stages of C-cell hyperplasia or micro-medullary carcinoma. - Reliance on imaging often results in diagnosis only after the cancer has become clinically significant or **locally invasive**. *Prophylactic total thyroidectomy at age 10* - While the window for MEN 2A is generally by age 5-10, there is no clinical benefit to waiting until age 10 when the mutation is already known at age 8. - Performing the surgery **now** minimizes the window for malignant transformation and is the standard of care for a child already within the target age range.
Explanation: ***Continue exploration for additional parathyroid glands*** - The **Miami Criteria** for a successful parathyroidectomy requires the **intraoperative PTH (ioPTH)** to drop by **>50%** from the highest pre-resection/baseline value at 10 minutes post-excision. - In this patient, the PTH dropped from 145 to 95 mg/dL (a **34% drop**), which is insufficient and indicates likely **multiglandular disease** or a remaining **adenoma**. *Perform bilateral neck exploration immediately* - While bilateral exploration is often indicated when ioPTH fails to drop, the precise next surgical step is to **continue exploration** to find the remaining source of PTH. - **Bilateral neck exploration** is the consequence of continued exploration if a focused approach was initially attempted but failed to meet biochemical criteria. *Obtain sestamibi scan in the operating room* - **Sestamibi scans** are preoperative localizing studies and are not routinely performed or anatomically useful for real-time guidance inside the operating room. - Persistent elevation of **PTH** mandates manual surgical exploration and anatomical inspection rather than repeat **radionuclide imaging**. *Close the incision as the procedure is complete* - Closing the incision would result in **failed surgery**, as the failure to achieve a 50% PTH drop identifies persistent **primary hyperparathyroidism**. - Success is defined by the biochemical cure demonstrated by the **ioPTH drop**, not just the removal of a single grossly abnormal gland. *Send frozen section and wait for permanent pathology* - **Frozen sections** confirm that the tissue removed is indeed parathyroid tissue but do not assess the functional status or presence of **multiglandular disease**. - Relying on histology alone is insufficient if the **biochemical markers** (ioPTH) indicate that hyperfunctioning tissue remains in the patient.
Explanation: ***Total thyroidectomy alone*** - For a **papillary thyroid carcinoma** (PTC) measuring **2 cm** (>1 cm and ≤4 cm), **total thyroidectomy** is a standard surgical recommendation to facilitate postoperative **thyroglobulin monitoring** and radioactive iodine (RAI) therapy if needed. - While lobectomy is an option for low-risk 1-4 cm tumors, total thyroidectomy is traditionally preferred for easier long-term **surveillance** of recurrence. *Thyroid lobectomy with isthmusectomy* - This procedure is sufficient for **PTC <1 cm** (microcarcinoma) or select low-risk patients with tumors <4 cm without extrathyroidal extension. - It is less ideal for a **2 cm nodule** if radioactive iodine ablation or simplified thyroglobulin monitoring is desired for long-term follow-up. *Total thyroidectomy with prophylactic central neck dissection* - **Prophylactic central neck dissection** (Level VI) is generally not recommended for T1 or T2 PTC in the absence of clinical or radiographic evidence of **lymphadenopathy**. - Routine use of neck dissection increases the risk of complications like **hypoparathyroidism** and **recurrent laryngeal nerve** injury without matching benefit in survival. *Observation with repeat FNA in 6 months* - **Observation** or active surveillance is only appropriate for **papillary microcarcinomas** (≤1 cm) in patients without high-risk features. - Once a **2 cm PTC** is confirmed via FNA, surgical intervention is necessary due to the risk of progression and metastasis. *Subtotal thyroidectomy* - **Subtotal thyroidectomy** is not a recommended oncological procedure for thyroid cancer as it leaves behind variable amounts of thyroid tissue. - Current surgical standards for thyroid malignancy dictate either **lobectomy** or a **complete total thyroidectomy** to ensure adequate clearance and monitorability.
Explanation: ***Joll retractor*** - The image displays a **Joll retractor**, which is a self-retaining retractor used commonly in **thyroid and parathyroid surgeries**. - Its design typically includes a frame with adjustable blades or hooks that help maintain exposure of the surgical site. *Langenbeck retractor* - A **Langenbeck retractor** is a handheld, single-ended retractor with an L-shaped blade, used for **superficial soft tissue retraction**. - It does not have the self-retaining mechanism or the complex frame shown in the image. *Morris retractor* - The **Morris retractor** is another type of handheld retractor, often used in **deep surgical fields**. - It is also a single-ended instrument with a curved or angled blade, unlike the self-retaining instrument pictured. *Dyball retractor* - The **Dyball retractor** is a specialized retractor, often used in **neck surgery** for deeper dissection. - While used in similar surgical areas to the Joll retractor, its design is distinct and does not match the instrument in the image. *Green retractor* - The **Green retractor** (also called thyroid retractor) is a double-ended handheld retractor commonly used in **thyroid surgery**. - It has a simple blade design and lacks the self-retaining frame mechanism characteristic of the Joll retractor.
Explanation: ***Total thyroidectomy*** - The patient exhibits classic symptoms of **hyperthyroidism** (nervousness, weight loss, racing heart, fine tremor) and has a **large goiter** (mass in the front of her neck that moves with swallowing). - The image shows **exophthalmos/proptosis**, indicating **Graves' ophthalmopathy**. - For a **large symptomatic goiter**, **total thyroidectomy** is the definitive treatment of choice, providing immediate resolution of symptoms and removal of the compressive mass. - Surgery is preferred over radioactive iodine when there is a large goiter, as it provides rapid symptom relief and eliminates concerns about gland enlargement from radiation-induced thyroiditis. *Subtotal thyroidectomy* - **Subtotal thyroidectomy** leaves residual thyroid tissue, which carries a **higher risk of recurrent hyperthyroidism** (10-30% recurrence rate). - With a **large goiter** and significant symptoms, **total thyroidectomy** is preferred for definitive cure and to avoid recurrence. *Propranolol* - **Propranolol** is a beta-blocker used to manage **symptomatic effects** of hyperthyroidism (palpitations, tremor, anxiety) but does not address the underlying thyroid hormone excess. - It is an **adjunctive therapy** or temporary measure, not a definitive treatment. *${ }^{131} \\mathrm{I}$ radioablation* - **Radioactive iodine (RAI)** is an effective definitive treatment for Graves' disease and is the most common treatment in the United States. - However, for patients with a **very large goiter** (>80g), RAI may be less effective, can cause transient thyroid enlargement (radiation thyroiditis) with potential airway compromise, and takes months to achieve full effect. - Surgery is preferred for large goiters requiring rapid symptom resolution or when there are compressive symptoms. *Antithyroid drugs (Methimazole)* - **Antithyroid drugs** (methimazole, propylthiouracil) block thyroid hormone synthesis and are used for initial management of hyperthyroidism. - While they can achieve remission in some patients (30-50% after 12-18 months), they are **not considered definitive treatment** as relapse is common after discontinuation. - They do not address the **large goiter**, which may require definitive therapy with surgery or RAI.
Explanation: ***Thyroglossal cyst*** - A **thyroglossal duct cyst** is a common congenital neck mass that typically presents in the midline of the neck. - The classic characteristic feature is its **movement with deglutition** (swallowing) and often with protrusion of the tongue, due to its attachment to the hyoid bone and remnants of the thyroglossal duct. *Brachial cyst* - **Branchial cleft cysts** are usually located laterally in the neck, anterior to the sternocleidomastoid muscle, and do not typically move with deglutition. - They are remnants of the branchial arches failing to involute completely. *Cystic hygroma* - A **cystic hygroma** is a type of lymphangioma, commonly found in the posterior triangle of the neck or axilla. - It is typically a soft, compressible, and ill-defined mass that does not move with deglutition. *Cervical lymphadenopathy* - **Cervical lymphadenopathy** involves enlarged lymph nodes, which can be firm or tender depending on the cause (e.g., infection, malignancy). - While they are common in the neck, they are generally not mobile with deglutition unless they are very superficial and freely movable, but they do not typically have the same characteristic movement as a thyroglossal cyst. *Dermoid cyst* - A **dermoid cyst** is another congenital midline neck mass that can present in the submental region. - Unlike thyroglossal cysts, dermoid cysts do not move with deglutition or tongue protrusion as they are not attached to the hyoid bone. - They are typically non-tender, doughy masses that may contain hair, sebum, and skin elements.
Explanation: ***Associated with MEN1*** - The triangle shown in the image represents the **Gastrinoma Triangle**, a common location for gastrin-producing tumors (gastrinomas) to occur. - Approximately 20-30% of gastrinomas are associated with **Multiple Endocrine Neoplasia type 1 (MEN1)** syndrome, which involves tumors of the parathyroid glands, pituitary gland, and pancreas. *Most common site is stomach* - The most common primary site for gastrinomas is the **duodenum** (50-70%), followed by the pancreas (20-40%). - Gastrinomas found in the stomach are rare and usually associated with MEN1, but the duodenum is the predominant site overall. *Best test for diagnosis is pentagastrin test* - The **pentagastrin stimulation test** is used to assess maximal acid output but it is not specific for diagnosing gastrinomas. - The **secretin stimulation test** is the most sensitive and specific provocative test for gastrinoma, as secretin normally inhibits gastrin release from G cells but paradoxically stimulates it in gastrinomas. *Metastasis to adjacent gut* - Gastrinomas are malignant neuroendocrine tumors that commonly **metastasize to regional lymph nodes** and the **liver**. - While they can invade locally, metastasis typically involves distant sites rather than just the adjacent gut wall. *Primary treatment is medical with proton pump inhibitors* - While **proton pump inhibitors (PPIs)** are essential for managing acid hypersecretion symptoms, they are not the primary definitive treatment. - **Surgical resection** is the primary treatment for localized, sporadic gastrinomas when feasible, offering potential cure. - PPIs serve as adjunctive medical therapy to control symptoms but do not address the underlying tumor.
Adrenalectomy approaches
Practice Questions
Endocrine surgery complications
Practice Questions
Hyperparathyroidism surgical management
Practice Questions
Minimally invasive endocrine procedures
Practice Questions
Multiple endocrine neoplasia syndromes
Practice Questions
Parathyroidectomy procedures
Practice Questions
Pheochromocytoma resection
Practice Questions
Postoperative hypocalcemia management
Practice Questions
Radioguided parathyroidectomy
Practice Questions
Recurrent laryngeal nerve protection
Practice Questions
Thyroid cancer management
Practice Questions
Thyroid nodule evaluation
Practice Questions
Thyroidectomy indications and techniques
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free